AR103428A1 - Anticuerpos de penetración celular - Google Patents

Anticuerpos de penetración celular

Info

Publication number
AR103428A1
AR103428A1 ARP160100103A ARP160100103A AR103428A1 AR 103428 A1 AR103428 A1 AR 103428A1 AR P160100103 A ARP160100103 A AR P160100103A AR P160100103 A ARP160100103 A AR P160100103A AR 103428 A1 AR103428 A1 AR 103428A1
Authority
AR
Argentina
Prior art keywords
penetrate
conjugates
cell
phosphorothioate
antibodies
Prior art date
Application number
ARP160100103A
Other languages
English (en)
Inventor
Yu Hua
Herrmann Andreas
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Publication of AR103428A1 publication Critical patent/AR103428A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud se refiere a conjugados que penetran la célula. Los conjugados incluyen una proteína que no penetra la célula unida a un ácido nucleico de fosforotioato o esqueleto de polímero de fosforotioato a través de un enlazador no covalente que incluye dominio de unión a biotina y un dominio de biotina, en donde el ácido nucleico de fosforotioato o esqueleto de polímero de fosforotioato mejora el suministro intracelular de la proteína que no penetra la célula. También se proporcionan composiciones y kits que comprenden los conjugados.
ARP160100103A 2015-01-16 2016-01-15 Anticuerpos de penetración celular AR103428A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562104653P 2015-01-16 2015-01-16

Publications (1)

Publication Number Publication Date
AR103428A1 true AR103428A1 (es) 2017-05-10

Family

ID=56406478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100103A AR103428A1 (es) 2015-01-16 2016-01-15 Anticuerpos de penetración celular

Country Status (18)

Country Link
US (1) US11730789B2 (es)
EP (2) EP3795168A1 (es)
JP (2) JP7260248B2 (es)
KR (1) KR20170098957A (es)
CN (2) CN107427550B (es)
AR (1) AR103428A1 (es)
AU (2) AU2016206475B2 (es)
BR (1) BR112017015203A2 (es)
CA (1) CA2972986A1 (es)
EA (1) EA201791610A1 (es)
IL (1) IL253403A0 (es)
MX (2) MX2017009272A (es)
PH (1) PH12017501271A1 (es)
SG (1) SG11201705413WA (es)
TW (1) TW201632207A (es)
UY (1) UY36519A (es)
WO (1) WO2016115500A1 (es)
ZA (2) ZA201705120B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170098957A (ko) * 2015-01-16 2017-08-30 시티 오브 호프 세포 침투성 항체
WO2016196691A2 (en) 2015-06-01 2016-12-08 California Institute Of Technology Compositions and methods for screening t cells with antigens for specific populations
US11661463B2 (en) 2015-08-06 2023-05-30 City Of Hope Cell penetrating protein-antibody conjugates and methods of use
WO2019014648A1 (en) * 2017-07-13 2019-01-17 City Of Hope PEPTIDES CONJUGATED TO A PHOSPHOROTHIOATE AND METHODS OF USE
EP3730150A4 (en) * 2017-12-22 2021-10-06 Rophibio, Inc. ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION
KR102075724B1 (ko) 2018-09-14 2020-02-10 한국원자력의학원 디아세레인을 유효성분으로 포함하는 항체의 종양 침투력 증진용 조성물 및 이의 용도
WO2021226107A1 (en) * 2020-05-05 2021-11-11 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
WO2022010539A1 (en) * 2020-07-08 2022-01-13 Octagon Therapeutics, Inc. Cancer cell modulators
KR20220055412A (ko) 2020-10-26 2022-05-03 한국원자력의학원 로자탄을 유효성분으로 포함하는 항암제의 종양 침투력 증진용 조성물 및 이의 용도

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
IL112372A (en) * 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
JP2005532067A (ja) * 2002-07-03 2005-10-27 コーリー ファーマシューティカル グループ，インコーポレイテッド 刺激性免疫応答用の核酸組成物
WO2007025365A1 (en) * 2005-08-31 2007-03-08 Oncolytics Biotech Inc. Treatment with an oncolytic virus and an immunostimulant for in vivo enhancement of immune system recognition of neoplasms
US8586708B2 (en) * 2005-10-28 2013-11-19 Massachusetts Institute Of Technology Monovalent streptavidin compositions
JP2009519033A (ja) 2005-12-16 2009-05-14 ディアト 核酸を細胞に送達するための細胞貫通ペプチド結合体
US20100239504A1 (en) 2007-07-17 2010-09-23 The General Hospital Corporation Imaging nucleic acid binding proteins
WO2010006237A2 (en) * 2008-07-11 2010-01-14 Alnylam Pharmaceuticals, Inc. Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents
CA2731779A1 (en) 2008-07-24 2010-01-28 Rxi Pharmaceuticals Corporation Rnai constructs and uses therof
SG11201601443PA (en) 2013-08-29 2016-03-30 Hope City Cell penetrating conjugates and methods of use thereof
KR20170098957A (ko) * 2015-01-16 2017-08-30 시티 오브 호프 세포 침투성 항체
EP3316894A4 (en) 2015-07-02 2019-06-19 City of Hope COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF
EP3331573A4 (en) 2015-08-06 2019-02-27 City of Hope THERAPEUTIC CONJUGATES OF CELL INTERNALIZATION

Also Published As

Publication number Publication date
AU2022200592A1 (en) 2022-02-24
EP3795168A1 (en) 2021-03-24
CN107427550B (zh) 2021-10-08
MX2021011584A (es) 2021-10-13
JP2021152022A (ja) 2021-09-30
EA201791610A1 (ru) 2017-12-29
JP2018505870A (ja) 2018-03-01
EP3244910A4 (en) 2018-08-08
US11730789B2 (en) 2023-08-22
CN107427550A (zh) 2017-12-01
PH12017501271A1 (en) 2018-02-05
BR112017015203A2 (pt) 2018-03-13
EP3244910A1 (en) 2017-11-22
AU2016206475A1 (en) 2017-07-20
JP7260248B2 (ja) 2023-04-18
CN113797349A (zh) 2021-12-17
KR20170098957A (ko) 2017-08-30
IL253403A0 (en) 2017-09-28
SG11201705413WA (en) 2017-08-30
ZA202105220B (en) 2023-01-25
US20180008667A1 (en) 2018-01-11
AU2016206475B2 (en) 2021-11-04
EP3244910B1 (en) 2020-09-16
CA2972986A1 (en) 2016-07-21
TW201632207A (zh) 2016-09-16
WO2016115500A1 (en) 2016-07-21
ZA201705120B (en) 2022-02-23
MX2017009272A (es) 2018-04-11
UY36519A (es) 2016-08-31

Similar Documents

Publication Publication Date Title
AR103428A1 (es) Anticuerpos de penetración celular
EA201690492A1 (ru) Проникающие в клетку конъюгаты и способы их применения
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
CY1121870T1 (el) Anti-egfrviii αντισωματα και χρησεις αυτων
BRPI0919473A2 (pt) Agentes de ligação frizzled e usos dos mesmos
CO2018000976A2 (es) Constructos de anticuerpo para cd70 y cd3
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
BR112019003129A2 (pt) composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer.
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201891212A1 (ru) Адресная дезорганизация клеточного рецептора гкгс
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
UY35484A (es) Molécula de unión de cadena simple que comprenden ABP de extremo N
EA201700546A1 (ru) Композит полипропилен - углеродное волокно
WO2015151080A3 (en) Specific conjugation of cell-binding molecules
CU23978B1 (es) Composiciones para anticuerpos que se dirigen a la proteína de complemento c5
BR112018077362A2 (pt) conjugados para edição de superfície de célula-alvo
EA201700547A1 (ru) Армированная волокнами полимерная композиция
CR20110496A (es) Biespecificos anticuerpos anti-her
BR112013017947A2 (pt) benzoazepinas substituídas como moduladores de receptor toll-like
EA201890895A1 (ru) Мультивалентные и моновалентные мультиспецифические комплексы и их применение
CR20170111A (es) Derivados de benzodiazepina citotóxicos
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
CO6351748A2 (es) Anticuerpos contra il-6 y sus usos
BR112019000693A2 (pt) composições de muc1- car e métodos para uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure